Cytokinetics, Incorporated
CYTK
$39.48
$0.330.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -9.59% | -24.05% | -11.41% | -3.32% | 0.35% |
| Total Depreciation and Amortization | -62.38% | 30.04% | 29.70% | 26.14% | 282.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 246.53% | 56.45% | 9.48% | 12.08% | -43.72% |
| Change in Net Operating Assets | -7.05% | 567.39% | 140.53% | -34.05% | 166.50% |
| Cash from Operations | 11.44% | -5.50% | 18.47% | -5.91% | 24.60% |
| Capital Expenditure | -1,575.32% | -218.64% | -167.09% | -- | 97.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 237.89% | -160.54% | -884.15% | -80.32% | -350.61% |
| Cash from Investing | 236.18% | -161.68% | -893.33% | -80.28% | -378.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,212.61% | -1,233.64% | -1,257.55% | -350.24% | -111.43% |
| Issuance of Common Stock | -96.17% | 42.45% | 10,870.44% | 3,372.57% | 4,597.67% |
| Repurchase of Common Stock | -- | -- | -- | -75.42% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -100.00% |
| Cash from Financing | -98.59% | -93.68% | 14,895.63% | 1,546.16% | 464.83% |
| Foreign Exchange rate Adjustments | 1,560.00% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 259.80% | -561.32% | 305.15% | -80.71% | 134.14% |